Meeting Banner
Abstract #0927

Are we seeing any better? A comprehensive comparison of myelin biomarkers in the healthy and multiple sclerosis post mortem spinal cord

Marco Battiston1, Torben Schneider2, Francesco Grussu1,3, Geert J Schenk4, Stig Wergeland4,5, Mohamed Tachrount6, Marios C Yiannakas1, Carmen Tur1, Jeroen J G Geurts4, Claudia Angela Wheeler-Kingshott1,7,8, and Rebecca Sara Samson1

1Queen Square MS Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, United Kingdom, 2Philips UK, Surrey, United Kingdom, 3Centre for Medical Image Computing, Department of Computer Science, University College London, London, United Kingdom, 4Department of Anatomy and Neurosciences, VU University medical centre, Amsterdam, Netherlands, 5Department of Neurology, Haukeland University Hospital, Bergen, Norway, 6Cardiff University Brain Research Imaging Centre, Cardiff University, Cardiff, United Kingdom, 7Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy, 8Brain MRI 3T Research Centre, C. Mondino National Neurological Institute, Pavia, Italy

Conventional MRI of the multiple sclerosis (MS) spinal cord offers low specificity to underlying pathological processes taking place. Quantitative MRI metrics able to characterize damage at the microstructural level are required. Of particular interest are those known to be sensitive to myelin content, which can be generated via various different contrast mechanisms. It is important to assess the specificity of such prospective myelin biomarkers to MS spinal cord pathology and validation studies comparing MRI with histological findings are essential for this purpose. Here a comparison of myelin-sensitive quantitative MRI metrics measured in MS and healthy ex vivo cord are presented.

This abstract and the presentation materials are available to members only; a login is required.

Join Here